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PENGEKSPRESAN ANTIGEN ANTIBODI MONOKLON IBMR3 DALAM 
TISU KANSER PAYUDARA 
 
 
ABSTRAK  
 
Pengesanan beberapa jenis kanser boleh dilakukan dengan menggunakan 
antibodi monoklon (AbM). Kajian menunjukkan bahawa jenis-jenis kanser yang 
berbeza mempunyai protein tak normal yang tertentu yang boleh dikenal pasti oleh 
AbM. IBMR3 AbM dibangunkan daripada peptida sintetik yang berhubung dengan 
jujukan asid amino terpilih daripada reseptor interleukin-4 manusia. Kajian ini adalah 
untuk mengesan ekspresi IBMR3 antigen dalam karsinoma termasuk Manusia 
carcinoma berhubung dgn pangkal tekak epitelium (HEp-2), adenokarsinoma kolon 
Manusia (HT-29) dan tisu kanser payudara. Ungkapan IBMR3 antigen dikesan pada 
HEp-2 dan HT-29 menggunakan ujian berbentuk tidak langsung pewarnaan, aliran 
sitometri pewarnaan. Hasil kajian menunjukkan persatuan kemungkinan IBMR3 
antigen ungkapan dalam karsinoma (kanser sel-sel epitelium) dengan pewarnaan 
cytoplasmic positif. HEp-2 dan HT-29 telah dipisahkan melalui 1-D immunoblot dan 
keputusan menunjukkan dua band dengan berat molekul (MWS) 45 dan 25 kDa 
dalam HT-29 dan satu band dengan MWS 25 kDa dalam HEp-2. IBMR3 antigen 
ungkapan itu dikesan pada 48 sampel kanser payudara Malaysia dan microarray 
(TMA) slaid tisu kanser payudara 430 dan 132 tisu payudara yang normal 
bersebelahan dengan kanser payudara melalui IHC. Pengekspresan antigen ini amat 
ketara berkait dengan gred histologi, peringkat tumor, dan metastasis nodus limfa. 
Pengekspresan IBMR3 yang tinggi diperhatikan pada tisu kanser payudara gred I 
xviii 
 
berbanding pengekspresan yang diperhatikan pada gred III pada kedua-dua sampel 
kanser payudara pesakit Malaysia (P < 0.003) dan slaid TMA (P < 0.01). Dapatan 
daripada kajian ini menunjukkan hubungan yang signifikan antara pengekspresan 
antigen IBMR3 dan ciri-ciri klinikopatologi bagi. Tisu karsinoma payudara manusia 
berjaya diasingkan melalui imunoblot 1-D. Keputusan menunjukkan dua jalur 
dengan berat molekul (BM) 45 dan 25 kDa. Jalur reaktif yang dipotong daripada 
elektroforesis gel dianalisis menggunakan LC-MS/MS. Keputusan daripada kajian 
ini mencadangkan bahawa antigen IBMR3 mungkin terdiri daripada protein zeta   
14-3-3 yang disahkan melalui fungsi biologinya di dalam kanser payudara dan laluan 
interaksinya dengan IL-4R. Penemuan ini menggambarkan hubungan yang signifikan 
di antara pengekspresan antigen IBMR3 dan jenis-jenis kanser epitelium yang lain. 
Antigen IBMR3 berkemungkinan memainkan peranan dalam perkembangan tumor 
dan pengekspresannya berkemungkinan mempunyai nilai yang signifikan dalam 
prognosis kanser. 
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EXPRESSION OF MONOCLONAL ANTIBODY IBMR3 ANTIGEN IN 
BREAST CANCER TISSUE 
 
 
ABSTRACT  
 
The detection of several types of cancer is possible by using monoclonal 
antibody (MAb). Studies have shown that different types of cancer have related 
specific abnormal proteins, which are identified by MAb. IBMR3 is a MAb which 
was raised against synthetic peptides that are associated with the selected amino acid 
sequence of human interleukin-4 receptors. This research is to detect the expression 
of IBMR3 antigen in carcinoma including Human laryngeal epithelial carcinoma 
(HEp-2), Human colon adenocarcinoma (HT-29) and breast cancer tissues. The 
expression of IBMR3 antigen was detected on HEp-2 and HT-29 using indirect 
immunofluorescent staining, flow cytometry staining. The results showed the 
possible association of IBMR3 antigen expression in carcinoma (epithelial cancer 
cells) with positive cytoplasmic staining. HEp-2 and HT-29 were separated via 1-D 
immunoblot and the results showed 2 bands with molecular weights (MWs) of 45 
and 25 kDa in HT-29 and one band with MWs of 25 kDa in HEp-2. IBMR3 antigen 
expression was detected on 48 samples of Malaysian breast cancer and microarray 
(TMA) slides of 430 breast cancer tissues and 132 normal breast tissues adjacent to 
breast cancer through IHC. The expression of this antigen significantly correlated to 
the histological grades, tumour stages, and lymph node metastases. High IBMR3 
expression was observed in grade I cancerous breast tissues compared with the 
xx 
 
expression observed grade III in both Malaysian breast cancer samples (P < 0.003) 
and TMA slides  (P < 0.01). Human breast carcinoma tissues were separated via 1-D 
immunoblot. Results showed 2 bands with molecular weights (MWs) of 45 and 25 
kDa. The reactive bands that were excised from gel electrophoresis were subjected to 
liquid chromatography-tandem mass spectrometry. IBMR3 antigen was identified 
using 1-DE gel coupled with LC-MS/MS successfully. The results of this study 
suggested that IBMR3 antigen could be 14-3-3 zeta/delta protein, which was 
supported by its biological function in breast cancer and it has interaction pathway 
with IL-4R. The findings from this study exhibited a significant relationship between 
IBMR3 antigen expression and different types of epithelial cancer cells. IBMR3 
antigen may play a role in tumour development and that its expression may have       
a significant value in cancer prognosis.  
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1 CHAPTER 1 
     INTRODUCTION 
1.1 BACKGROUND OF THE STUDY 
Cancer is a disease of a cell or a group of cells that divides and replicates 
uncontrollably because of the accumulation of both epigenetic and/or genetic 
changes (Verma & Singh, 2013). Cancer types depend on the origin site of the 
malignant cells, the histology, or cell analysis (grading), and the extent of the disease 
(staging). Cancers are classified into 3 main groups, namely, carcinomas, sarcomas, 
and leukemias or lymphomas. Cancers that developed in epithelial tissues are called 
carcinomas, which are detected in approximately 90 % of human cancers. Cancers 
that developed in connective tissues are called sarcomas, which are rare in humans. 
Leukemias and lymphomas are cancers that developed in cells that normally mature 
in the bloodstream and in the lymphatic system respectively (Cooper, & Hausman, 
2000).  
Most carcinomas affect secretory organs or glands, such as breasts that 
produce milk, the lungs that secrete mucus, colon, prostate, and bladder (Hayat, 
2004). Breast cancer  tissues are rich in epithelial cells (Rezaul et al., 2010). The high 
morbidity of breast cancer is related to late diagnosis in which cancer has reached 
aggressive stages (Jassem et al., 2013). It is a common cause of cancer death among 
women (Chahil et al., 2015; Harhra & Basaleem, 2012), followed by colon cancer 
(Hamid et al., 2012; Zainal Ariffin & Nor Saleha, 2011). Several colon cancer cell 
lines originate from the epithelial region, including the HT-29 cells (Aggarwal et al., 
2015). The HT-29 human colon carcinoma cell lines are widely used to model the 
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physiological and immune function of intestinal epithelial cells (Bruno & Kaetzel, 
2005). Meanwhile, the HT-29 human colon adenocarcinoma cell lines offer 
favourable experimental systems to investigate the factors involved in epithelial cell 
differentiation (Cohen, Ophir, & Shaul, 1999). HT-29 cells correspond to well-
differentiated colorectal adenocarcinoma, which is grade one (I) colorectal 
adenocarcinoma (Rimkus et al., 2006). HT-29 human colon carcinoma cell lines are 
widely used to model the physiological and immune functions of intestinal epithelial 
cells (Bruno & Kaetzel, 2005), Likewise, HEp-2 is a human laryngeal epithelial 
carcinoma cell line, which is derived from laryngeal carcinoma cells and is often 
utilised as a model in carcinogenicity and mutagenesis tests (Lima et al., 2005). HEp-
2 cells are related to poor differentiation, advanced clinical stages, and tumour grade 
(Tian et al., 2014). 
Cytokines and their receptors are important contributors to tumour 
development. Interleukin 4 (IL-4) is a pleiotropic cytokine that demonstrates 
opposite effects on tumour growth including the increase and decrease of the 
proliferation and survival of malignant cells (Li et al., 2009). Interleukin-4 receptor α 
(IL-4Rα) is expressed in numerous cancer cell lines derived from non-hematologic 
human malignancies, such as melanoma, pancreatic adenocarcinoma, glioblastoma, 
colon carcinoma, gastric carcinoma, breast carcinoma, ovarian carcinoma lung 
carcinoma, head and neck cancers, and renal cell carcinoma. IL-4R is expressed in 
many human epithelial cancer cells; however, the binding characteristics, structure, 
function, and signal transduction through the IL-4R in cancer cells are not known. 
Human breast carcinoma cell lines express high-affinity IL-4R. A previous study 
demonstrated that the increase in IL-4R expression renders HT-29 and HEp-2 cells to 
3 
 
be more sensitive to IL-4 and that low concentrations of IL-4 are required to exert its 
effect on cell proliferation (Suriza, Musa, & Mat, 2006). 
To date, various targeted therapies are evaluated in cancer patients. 
Monoclonal antibody (MAb) is one of the most promising approaches to enhance 
patient survival outcome (Bellati et al., 2011). MAb is prepared from a single clone 
(hybridoma) of white blood cells, as described by Köhler and Milstein (1975). The 
use of MAb in cancer treatment is focused on targeting tumour cells that express 
tumour-associated antigen (Oldham & Dillman, 2008). MAb is also used to 
antagonize receptor signaling pathways, which are essential in tumour cell migration, 
survival, and proliferation. MAb mainly blocks key receptors on tumour cell 
surfaces. It is also used to recruit the immune system cellular arm on the transformed 
cell. Although MAb is synthetically produced, it mimics naturally produced 
antibodies as part of the immune system’s response to disease (Kewal et al., 2014).  
The IBMR3 is a MAb with an IgM isotype. It is produced from 4 peptides of 
interleukin 4 receptor.  IBMR3 antibody showed weak positive result with resting 
PBMC, but expression upregulation was observed in activated PBMC using anti-
CD3 and IL-4 (Mat, 1992). The IBMR3 antigen expression was analysed using flow 
cytometry on normal peripheral blood and leukaemic cells. The results showed no 
staining on the surface of normal resting PBMC, but high expression was observed at 
the cytoplasm of the cell. In the transformed haemopoietic cells, 9 acute 
myelogenous leukaemia (AML), 2 acute lymphoid leukaemia (ALL-T) and 6 ALL-B 
cells showed intense cytoplasmic staining and negative staining on the surface. The 2 
AML cells showed staining in both cytoplasmic and surface regions (Hara & Mat, 
2004). Previous study showed that IBMR3 antigen was expressed significantly 
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higher at the cytoplasm of lymphocytes and monocytes when compared with their 
surface. The expression of IBMR3 antigen was differentially expressed in malignant 
haemopoietic cells (acute leukaemia) compared to normal PBMC (Hara, 2002). 
According to Adams and Weiner (2005), antibodies are used for cancer 
therapy by directing them to cell antigens on the cell surface that is associated with 
tumour stroma, as well as to antigens on the tumour-associated vasculature and 
ligands, which support tumour growth in both circulating malignant cells and solid 
tumours. Tumour antigen, which is targeted by MAb, is one of the most successful 
new therapies (Lee et al., 2011). Previous studies indicated that MAb is important in 
the biomedical research of targeted drug delivery systems, particularly in the 
treatment of cancer, as well as metabolic and hormonal disorders (Deb et al., 2013). 
Many antibodies were approved by the Food and Drug Administration (FDA) of 
United States for cancer treatment. FDA approved palbociclib (Ibrance) in February 
2015. Palbociclib is a kinase inhibitor that is used in combination with letrozole for 
treatment of postmenopausal women with estrogen receptor-positive and human 
epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as 
initial endocrine-based therapy for metastatic disease (Beaver et al., 2015). 
Therapeutic predictions are now identifiable because of the diagnosis from proteome 
analysis (Donadio et al., 2011). Studies of breast cancer-derived proteins that use 
electrophoretic separation and immunoblotting techniques have been published and 
widely available (Osborne & Brooks, 2006). O’Farrell developed a technique for 
protein separation (O’Farrell, 1975).  
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The basic process of protein separation consists of identifying protein 
isoelectric point and then analysing protein according to its size. This process is 
conducted by two-dimensional electrophoresis (2DE) (Kondo, 2010) and paves the 
way for a broader study of more than 1000 protein samples in a single experiment 
from a cell or tissue extract. In previous studies, SDS-PAGE and immunoblot 
analysis were used to determine and represent the shared agglutinin-binding 
glycoproteins in clinical tumour samples and breast cell lines (Osborne & Brooks, 
2006). Many of these studies detect different protein levels in healthy and diseased 
tissues. The expression profiling of tissue protein is potent in discovering new 
biomarkers to improve breast cancer prognosis, diagnosis, and staging (Freitas et al., 
2013). 
1.2 PROBLEM STATEMENT 
IBMR3 MAb was raised against synthetic peptides that similar to certain 
amino acid sequences in human IL-4R  (Mat, 1992). Cytokines and their receptors 
are vital factors for tumour advancement. IL-4R is expressed in many human 
epithelial tumours. IL-6, IL-4 and IL-8 levels are increased among patients with 
prostate, breast or colon cancer. The significance of the IL-4R overexpression in 
epithelial cancer cells has not been elucidated. 
The significance of IL-4R overexpression in epithelial cancer cells is not 
elucidated as well as the binding function and correlation of IBMR3 expression with 
clinical stage and grade in cancer cells remain unclear. Previous study found that 
there was strong expression of IBMR3 antigen in early stage of breast cancer 
development and the expression ceased once the tumour metastasised to lymph node 
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(Hara, 2002). Unfortunately, only three samples were previously analysed which 
considered too little. Therefore, in order to detect IBMR3 antigen expression on 
larger sample size of breast cancer, further study is demanded. The preliminary 
experiment was performed on poorly and well differentiated cell lines, HEp-2 and 
HT-29 cells respectively. Moreover, IBMR3 antigen expression was more prominent 
in malignant haemopoietic cells (acute leukaemia) as compared with normal PBMC 
(Hara, 2002). The epithelial cancer cell lines, HEp-2 and HT-29 were selected to 
compare the expression of IBMR3 antigen between haemopoietic cell and 
carcinoma. There is also no study available on the IBMR3 antigen and its role on 
cancer. Hence, this study aims to provide better understanding on the function of this 
protein its potential implication on cancer. 
1.3 OBJECTIVES OF THE STUDY 
1.3.1 General Objective  
This study aims to investigate the expression of IBMR3 antigen in colorectal 
cancer cell line, laryngeal cancer cell line and breast cancer tissues and to profile the 
IBMR3 antigen in breast cancer tissue. 
1.3.2 Specific Objectives 
1.  To detect the expression of IBMR3 antigen in epithelial cancer cell 
lines (HEp-2 and HT-29). 
2.  To recognise IBMR3 antigen expression in breast cancer tissues of 
Malaysian patients. 
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3.  To determine the association between the IBMR3 antigen expression 
level with patient clinicopathological features. 
4.  To separate and detect IBMR3 antigen in breast cancer tissues using 
immunoblot. 
5.  To identify the candidates for IBMR3 antigen in breast cancer tissues 
using liquid chromatography- tandem mass spectrometry. 
1.4 HYPOTHESIS OF THE STUDY 
1. The expression of IBMR3 antigen is positive in colorectal cancer cell line, 
laryngeal cancer cell line and breast cancer tissues. 
2. The expression of IBMR3 antigen is associated with cancer development. 
3. The IBMR3 antigen has intracellular connections with IL-4 receptors. 
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2  CHAPTER 2 
     LITERATURE REVIEW 
 
2.1 MONOCLONAL ANTIBODIES 
MAbs are the protein molecules which were synthetically created from 
hybridoma cells (stable cell lines) by fusing antibody‐producing cells from the 
immunised animals with cells that confer immortality and yield high antibody 
production (Köhler & Milstein, 1975) or by recombinant deoxyribonucleic acid 
(DNA) technology (Zola, Thomas, & Lopez, 2013). MAb technology is an important 
development in creating specific serologic reagents within a large diversity of 
antigens to produce several types of highly specific and reproducible immunological 
assays for fast and accurate diagnosis (Deb et al., 2013). Previous study illustrated 
that the hybridoma cell culture which yields the monoclonal antibodies shows the 
possibility of an unrestrained supply of reagent (Nelson et al., 2000). 
2.1.1 Monoclonal Antibody Production 
MAbs were produced by engineering hybridoma cells to form the desired 
antibody in a large amount (Pandey, 2010). Köhler and Milstein (1975) discovered 
the way to create monoclonal antibodies from hybridoma by fusing malignant 
myeloma cells with antibody-producing B-cells (Figure 2.1). The first stage in 
Köhler and Milstein's technique for producing the monoclonal antibodies involves 
immunisation of an experimental animal with the antigen of interest. In other words, 
the mouse is injected with an antigen. As a result, the mouse initiates an immune 
response and produces antibodies specific to the antigen. Spleen cells from the 
immunised mouse are taken and hybridized with myeloma cells. 
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Hybridomas which resulted from the hybridization have the survival chance. 
Generally, the spleen lymphocyte has a limited life span. Therefore, any B-cells 
which do not merge with myeloma will die in the culture. The isolated hybridoma 
cells are examined for their specificity to the antigen. This is because each 
hybridoma originated from B-cell creates copies for only one antibody (Köhler & 
Milstein, 1975). 
 
 
Figure 2.1: The production of monoclonal antibodies from a mouse spleen 
cell. Adapted from Michnick and Sidhu (2008). 
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2.1.2 Application of Monoclonal Antibodies 
MAbs are widely used in biomedical science to identify proteins, 
carbohydrates and nucleic acids, as well as to figure out molecules which control cell 
replication and differentiation. The application of monoclonal antibodies includes the 
following sections. 
2.1.2(a) Diagnostic Application of Monoclonal Antibody 
MAbs can be used in a clinical laboratory, diagnostic tests such as various 
immunoassays, radioimmunoassays, particle agglutination, immunofluorescent 
antibody assays, enzyme-linked immunosorbent assays and immunohistology (Payne 
et al., 1988). MAbs are applied in diagnostic histopathology and these molecules are 
used for the purpose of classifying tissues and tumours based on their expression in 
defined markers, thus reflecting tissue or cellular genesis. For instance, monoclonal 
antibodies of specific organ-associated antigens such as the prostate specific antigen, 
human chorionic gonadotrophin, fetoprotein, placental alkaline phosphatase and 
others are capable of assisting the pathologist to establish the nature of a primary 
tumour (Nelson et al., 2000).  
The histopathological staining using haematoxylin and eosin is not sufficient 
for detecting a small number of invasive or metastatic cells (Winnard et al., 2008). 
HER-2/neu protein is known as a family member that belongs to growth factor 
receptors. Previous research showed that identification of the oncogene 
overexpression, HER-2/neu (c-erbB-2) in breast cancer lead to develop an 
immunotherapy approach to dealing with this disease based on using the MAb 
(Hermiston & Kirn 2005) 
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2.1.2(b) Prognostic Application of Monoclonal Antibody 
There are certain markers which are detected by MAbs provide useful 
information on prognosis in cancer patients. For instance, detecting the anti-
apoptosis protein BC-2 has been described to be an indicator of poor prognostic with 
a diversity of tumour kinds such as prostate and ovarian cancers, as well as for 
Hodgkin’s s and non-Hodgkin’s lymphomas. Contrarily, downregulating of the 
cyclin-dependent kinase inhibitor is associated with poor prognosis in non-Hodgkin’s 
lymphomas, breast cancer, colorectal and in prostate (Nelson et al., 2000). 
Monitoring HER-2/neu extracellular domain that provides a tool for 
prognosis assessment, earlier detection of disease progression, predicting response to 
therapy, and timely intervention with an appropriate therapy (Carney et al., 2006). 
The EGFR family of receptor tyrosine kinases is an attractive target for antitumour 
strategies such as EGFR HER2/erb-B2 and HER3/erb-B3. Aberrant EGFR signaling 
is correlated with the progression of various malignancies. The somatic tyrosine 
kinase domain mutations in the EGFR gene are discovered in patients with non–
small lung cancer cells corresponding to EGFR-targeted small molecular agents, 
such as erlotinib and gefitinib. EGFR overexpression is the principal mechanism of 
activation in various malignant tumours (Ono & Kuwano, 2006). 
2.1.2(c) Monoclonal Antibody Therapy of Cancer 
Although MAb in cancer treatment has resulted in new successes, new 
therapeutic and clinical challenges arise (Myskowski & Halpern, 2008). MAbs are 
important reagents in biomedical research for the purposes of targeted drug delivery 
systems, therapeutics and diagnostics of cancer, metabolic and hormonal disorders 
(Deb et al., 2013). MAb is used to block key receptors on tumour cell surfaces, as 
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well as compromising their functions. MAb is also used to recruit the cellular arm of 
the immune system and in planting a homing beacon on the transformed cell. 
Although MAbs are produced in the laboratory, they can mimic the naturally 
produced antibodies as part of the immune response to disease (Kewal et al., 2014). 
According to the recent study, the MAb therapy for cancer has shown a 
remarkable advance, clarifying the advantage of MAb in treating common 
malignancies which include breast cancer, lymphoma, and colorectal cancers. Table 
2.1 shows the antibody-based therapeutics which is applied in the therapies of human 
malignancies (Simpson & Caballero, 2014). Nowadays, tumour antigen (TA) 
targeted MAb has been among the successful new therapies. Clinical activity is 
observed as a single agent or in combination with radiotherapy or chemotherapy in 
metastatic colorectal cancer, follicular lymphoma, head and neck cancer, in addition 
to the breast cancer (Lee et al., 2011). 
2.2 MONOCLONAL ANTIBODY IBMR3 
The IBMR3 is a MAb with an IgM isotype. It  is produced from 4 peptides, 
designated as number 2, 3, 4 and 5  as follows: peptide 2, S-E-N-D-P-A-D-F-R-I; 
peptide 3, W-S-E-W-S; peptide 4; F-V-S-V-G-P-T-Y-M-R-V-S; and peptide 5, M-K-
V-L-Q-E-P-T-C-V-S-D-Y (Figure 2.2). Peptides 2, 3 and 5 represent sequences 
found on the extracellular domain while the peptide 4 represents sequence found in 
the intracellular portion of the human interleukin 4 receptor (IL-4R) at the C-
terminus. They were chosen for their potential immunogenicity. Peptides 2, 3 and 5 
are peptides from the N-terminal outside of the plasma membrane while peptide 4 is 
from the cytoplasmic portion of the molecule.  
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Table 2.1: Monoclonal antibodies approved for clinical use in oncology 
Antibody name Target Antibody 
format 
Application 
Cetuximab EGFR Chimeric Colorectal, breast and lung 
cancer 
Panitumumab EGFR Human Colorectal cancer 
Nimotuzumab EGFR Humanized Head and neck cancer 
Rituximab CD20 Chimeric Non-Hodgkin lymphoma 
Trastuzumab HER2 Humanized Breast cancer 
Alemtuzumab CD52 Humanized Chronic lymphocytic 
leukemia 
Bevacizumab VEGFA Humanized Colorectal and lung cancer 
Ofatumumab CD20 Human Chronic lymphocytic 
leukemia 
Ipilimumab CTLA-4 Human Metastatic melanoma 
Pertuzumab HER2 Humanized Breast cancer 
Denosumab RANK 
Ligand 
Human Solid tumour bony 
metastases 
Brentuximab vedotin CD30 Chimeric Hodgkin's or systemic 
anaplastic large cell 
lymphoma 
Gemtuzumabozogamicin CD33 Humanized Acute myelogenous 
leukemia 
90Y-Ibritumomab 
tiuxetan 
CD20 Mouse Low grade or transformed 
B cell non-Hodgkin's 
lymphoma 
Tositumomaband 131I-
tositumomab 
CD20 Mouse Lymphoma 
Adapted from Simpson and Caballero (2014) 
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Figure 2.2: Amino acid sequences of human interleukin 4 receptor. The signal 
sequence and transmembrane domain are underlined, while the sequences 
used to synthesise peptides are indicated in bold letters (SENDPADFRI is 
the peptide 2; WSEWS is the peptide 3, FVSVGPTYMRVS is peptide 4 and 
MKVLQEPTCVSDY is the peptide 5). Adapted from Mat, 1992. 
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Peptide 5 is the outermost sequence on the N-terminal while peptide 3 
represents the conserved WS x WS motif located outside the membrane-spanning 
domain (Mat, 1992). Amino acids codes for IL-4R showed in Table 2.2. 
 
Table 2.2: Amino acids codes 
 
One letter code Amino acid 
A alanine 
B asparagine or aspartic acid 
C cysteine 
D aspartic acid 
E glutamic acid 
F phenylalanine 
G glycine 
H histidine 
I isoleucine 
K lysine 
L leucine 
M methionine 
N asparagine 
P proline 
Q glutamine 
R arginine 
S serine 
T threonine 
V valine 
W tryptophan 
Y tyrosine 
Z glutamine or glutamic acid 
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2.2.1 Screening of IBMR3 Hybridoma Supernatants by Peptide ELISA. 
The hybridoma supernatants were screened using ELISA technique for mice 
immunised with synthetic IL-4 receptor peptides. ELISA plates were coated with 
different peptides (2, 3, 4 and 5) and incubated with tissue culture supernatants from 
each of the wells that showed good cell growth. Cloned IBMR3 was derived from 
hybridoma cells and screened for immunoreactivity for peptide 3.  This antibody was 
tested using ELISA coated with the other peptides (2, 3, 4 and 5). The antibody was 
found to be cross-reacted with all peptides.   
IBMR3 antibody showed strong reactions with peptide 3, while peptide 5 
recorded the highest OD. Even though there was similar concentration of different 
peptides used to coat the ELISA plates, the similarity of peptides binding efficiency 
was not determined. Peptide 3 and 5 might bind more efficient than peptide 2 and 4. 
Thus, higher OD405 was observed for peptide 3 and 5. There is possibility of 
different binding efficiency of different peptides on plastic, with peptide 5 being the 
most efficient. Since this antibody cross-reacted with all peptides, higher OD 
observed in peptide 5 might be due to the level of peptide bound rather than the 
inherent characteristics of the antibody (Mat, 1992). 
2.2.2 The Expression of IBMR3 Supernatants 
The supernatants were incubated with Jijoye cells (B lymphocyte). Resting 
and activated PBMC were also used.  The antigen was weakly expressed by Jijoye 
cells and detected by IBMR3 antibody. This suggested that the antigen is expressed 
on the surface of Jijoye cells. However, the staining intensity was higher when the 
cells were fixed in acetone-methanol prior to immunostaining.  Other than that, 
IBMR3 antibody showed weak positive result with resting PBMC, but expression 
17 
 
upregulation was observed in activated PBMC using anti-CD3 and IL-4. The 
supernatants were also incubated with frozen thymus sections. The IBMR3 antibody 
showed weak (1+) labelling for the thymic cortex, moderate (2+) labelling for the 
medullary region and strong (3+) reactivity for the endothelium of the medullary and 
interlobular blood vessels (Mat, 1992). 
The IBMR3 antigen expression was analysed using flow cytometry on 
normal peripheral blood and leukaemic cells. The results showed no staining on the 
surface of normal resting PBMC, but high expression was observed at the cytoplasm 
of the cell. In the transformed haemopoietic cells, 9 acute myelogenous leukaemia 
(AML), 2 acute lymphoid leukaemia (ALL-T) and 6 ALL-B cells showed intense 
cytoplasmic staining and negative staining on the surface. The 2 AML cells showed 
staining in both cytoplasmic and surface regions (Hara & Mat, 2004). Previous study 
showed that IBMR3 antigen was expressed significantly higher at the cytoplasm of 
lymphocytes and monocytes when compared with their surface. The expression of 
IBMR3 antigen was differentially expressed in malignant haemopoietic cells (acute 
leukaemia) compared to normal PBMC (Hara, 2002). 
2.2.3 Interleukin 4 and IBMR3 Monoclonal Antibody 
The antibody supernatants were used in cross-linking study to determine the 
inhibition ability of IL-4 binding and/or immunoprecipitation of IL-4 receptor. Cells 
preincubation with IBMR3 tissue culture supernatants 10 minutes prior to the 
addition of 125I-IL-4 did not block IL-4 binding. The antibody supernatants also did 
not immunoprecipitate the IL-4 receptor complex. These were preliminary 
experiment and more investigation on cross-inhibition and immunoprecipitation of 
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MAb IBMR3 and radiolabelled IL-4 needed to be done. It is to determine whether 
MAb IBMR3 recognises any component of human IL-4R complex (Mat, 1992). 
When IBMR3 was added to the lymphocyte culture and incubated for one 
hour before adding the recombinant IL-4, the IBMR3 MAb failed to inhibit the 
binding of the human recombinant IL-4. Moreover, the experiment was done by 
incubating IBMR3 MAb concurrently with the recombinant IL-4 and the results 
showed increased proliferation of cell culture. This suggested that IBMR3 MAb has 
a low binding affinity as compared to IL-4. Therefore, IBMR3 MAb does not 
compete efficiently unless a "head start” is given.  Alternatively, this antibody may 
bind to molecule involved in IL-4 signal transduction rather than the binding site 
(Mat, 1992). 
2.3 INTERLEUKIN 4 RECEPTOR 
Cytokines were discovered as secreted proteins that control various immune 
functions. It is now clear that cytokine functions extend to many other aspects of 
biology, including cancer (Lin & Karin, 2007). IL-4 is a cytokine which acts a 
critical role in the immune responses regulation. Its effect depends on the binding 
and signalling of a receptor complex consisting of IL-4Rα and gamma chains (γc), 
resulting in a series of phosphorylation mediated by receptor-associated kinases 
(Nelms et al., 1999). Binding of IL-4 activates signal transduction cascade including 
the Janus kinases of Jak1 and Jak3, which phosphorylate the cytoplasmic domain of 
the receptor as well as downstream signalling molecules. Two main pathways are 
activated in response to IL-4, signal transducer and transcription 6 (STAT6) activator 
pathway and the insulin receptor substrate-2 (IRS-2) pathway (Pernis et al., 1995). 
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IL-4 protects cells from apoptosis by 2 different pathways, one of them is mediated 
by IRS-1 (Zamorano et al., 1996). 
IL-4 also acts as a multiunit transmembrane receptor (IL-4R) and induces 
growth inhibition in breast cancer cells (Gooch et al., 1998). This growth effect is 
associated with phosphorylation of 2 key components in the distinctive signalling 
pathways of STAT6 and IRS-1. The activation of these 2 pathways occurs 
independently in breast cancer cells (Gooch, Christy, & Yee, 2002). IL-4R is 
expressed as many as 30 % of primary breast tumour cells (Mat, 1992). 
2.4 BREAST CANCER 
Cancer is a disease of extreme heterogeneity. It is associated with the increase 
rate of death worldwide. Recent data showed that there were approximately 7.6 
million deaths caused by cancer in 2008, attributing to 13 % death (Ferlay et al., 
2010). In 2008, the cancer death in females was reported to be 1.38 million (23 %) 
cancer cases and 458,400 (14 %) cancer-related deaths (Jemal et al., 2011). The top 
10 cancers affecting both male and female in Malaysia are breast, colorectal, lung, 
nasopharynx, cervix, lymphoma, leukemia, ovary, stomach and liver (Figure 2.3) 
(Zainal Ariffin & Nor Saleha, 2011).  
Breast cancer is one of the common causes of cancer death among women 
(Jassem et al., 2013; Youlden et al., 2014) accounting for 18 % of all cases in 2012, 
and was the fourth most common cause of cancer-related deaths (9 %). The 
incidence rates rapid rises in recent years were observed in several Asian countries.  
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Figure 2.3: Ten most frequent cancers, all residence in Malaysia 2007. Adopted from 
Zainal Ariffin and Nor Saleha (2011). 
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Large increases in breast cancer mortality rates also occurred in many areas, 
particularly Malaysia (Youlden et al., 2014). Large increases in breast cancer 
mortality rates also occurred in many areas, particularly Malaysia (Youlden et al., 
2014). The higher morbidity is linked to a late diagnosis of breast cancer’s where 
cancer has reached the aggressive stages (Jassem et al., 2013). Breast cancer is 
dominant among Malaysian women aged between 40 and 49 (Chahil et al., 2015). 
Many studies showed that early detection of breast cancer had successfully led to 
various effective treatment options thereby saving life (Anderson et al., 2006).  
The breast cancer treatment poses more restrictions to low and middle-
income countries due to limited availability of trained medical personnel and modern 
equipment thus contributing to the high cost of cancer drugs and radiotherapy 
machines (Anderson et al., 2008). Rakha et al. (2010) highlighted the three main 
predictive determinants which are used in the routine practice of the early stage of 
breast cancer in which every patient has to be under a systemic therapy based on the 
conditions such as tumour size, lymph node status and histological tumour grade. 
The histological tumour grade depends on the degree of the tumour tissue 
differentiation. The pathologist has to observe the biology of histological grade on 
breast cancer behavior, which is essentially associated with the survival pattern 
(Rakha et al., 2010). 
2.4.1 Prognostic Factors of Breast Cancer 
Prognostic factors were used to evaluate an individual patient’s risk of 
micrometastatic disease. The measurement accessible at the time of surgery which is 
associated with disease-free or overall survival in the absence of systemic adjuvant 
therapy is called a prognostic factor.  This factor can be correlated with the history of 
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the disease (Cianfrocca & Goldstein, 2004). Prognostic factors must be distinguished 
from predictive factors. Predictive factors are useful in selecting the optimal adjuvant 
therapy for a particular patient. The predictive factor is a measurement that is related 
to response to a certain therapy (Clark, 2008). The most important determinants of 
10-year survival for breast cancer patients are the conventional prognostic factors of 
survival such as tumour size, lymph node status, and grade (Soerjomataram et al., 
2008). 
2.4.2 Tumour Size 
Tumour size is one of the most powerful breast cancer prognostic indicators. 
A larger tumour size has been  associated with a more positive lymph nodes (Carter, 
Allen, & Henson, 1989; Weiss et al., 2003). Therefore, their interaction influences 
the survival from breast cancer. Nevertheless, the independence of survival  against 
the node status is shown by the  66 % 10-year  survival rate found  in node negative 
patients with a tumour of 2–5 cm as compared to 79 % in those with a tumour 
smaller than one cm (Chia et al., 2004). 
2.4.3 Axillary Lymph Node Status 
The histological presence of axillary lymph node is an important factor in 
breast cancer prognosis (Elkhodary et al., 2014). Patients with positive lymph node 
were reported to have a 4 to 8 times higher mortality rate in comparison to patients 
with negative lymph nodes (Stankov et al., 2012). The biomarker expression in 
lymph node metastasis provides prognostic information when no primary analysis 
tumour can be done. Therefore, a treatment selection based on biomarkers in the 
lymph node a topic to be studied further (Falck et al., 2010). 
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2.4.4 Histologic Grade 
Tumour grade has prognostic significance and is initially used to make 
decisions on lymph node negative patients with borderline tumour size (Cianfrocca 
& Goldstein, 2004). According to the study conducted by Pilli and Godhi (2013), 
histologic grade refers to the degree of tumour differentiation. Any tumour grade is 
based on the tumour malignancy degree which is reflected in the morphological 
structure. The histological grade in breast cancer provides clinically important 
prognostic information (Sotiriou et al., 2006). In grade one, the cancer cells like 
normal cells and they are growing slowly. It is called well-differentiated or low 
grade. Grade 2 which the cancer cells are not like normal cells. They are growing 
faster. It is called moderately differentiated or intermediate/moderate grade. Grade 3 
which the cancer cells look totally different than the normal cells. It is called poorly 
differentiated or high grade (www.breastcancer.org, 2006). 
The tumour mitotic rate and the occurrence of abnormal mitoses are the 
important characteristics (Bignold, Coghlan, & Jersmann, 2006). According to Rakha 
et al. (2010) when histological grading is carried out, it provides a simple, 
inexpensive, and highly accurate method for assessing tumour biological 
characteristics and patient prognosis. This is important for breast cancer patients in 
the world where access to a new molecular technology is not currently available. 
The Scarff-Bloom-Richardson (SBR) grading is one of the important 
pathological parameters to be evaluated in the management of breast carcinoma. The 
SBR grade is a useful and sensitive guide for selecting adjuvant systemic therapy and 
the method should be standardized for cytology specimens (Elston & Ellis, 1991). 
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2.4.4(a) Scarff-Bloom-Richardson Grading System 
Bloom and Richardson proposed a simplified system that utilised only three 
of Greenough's variables: gland-formation (tubularity), degree of variation in nuclear 
size and shape (pleomorphism) and 'hyperchromatic figures' as estimation for 
proliferation (Meyer et al., 2005). For each case, the SBR tumour grading was done 
on fine-needle aspirates and tissue sections by two independent pathologists. The 
results were reproducible in the majority of the cases. The discrepant findings were 
discussed and a final consensus was agreed upon the usage of multiheaded 
microscope. Each of the three features, i.e. tubule formation, nuclear pleomorphism 
and mitotic count were scaled as 1, 2 or 3 and the final SBR score ranged between    
3 – 9, which was further divided into three grades (I – III). For grade I, the score 
ranged between 3 – 5, for grade II the score was 6 – 7 and for grade III the score 
ranged between 8 – 9. Cytology criteria for identifying tubule formation and mitotic 
counts were modified from the standard histological criteria. Scaling of nuclear 
pleomorphism on cytology was similar as in tissue sections. Tubule formation in 
FNA smears were identified as microacini and/or as branching, elongated, three-
dimensional tubular structures (Bansal et al., 2012). 
2.4.5 Triple Negative Breast Cancer 
Triple negative breast cancer (TNBC) is a heterogeneous disease which is 
associated with poor prognosis and  has a lack of expression of the estrogen receptor 
(ER), progesterone receptor (PR) and epidermal growth factor receptor type 2 
(HER2) (Millis et al., 2015). 
